Verastem Oncology Q3 revenue hits $11.2 mln, net loss widens

Verastem

04/11/2025 12:41

Overview

Verastem Q3 2025 net product revenue reaches $11.2 mln, marking successful product launch

Company reports Q3 net loss of $98.5 mln, reflecting increased operating expenses

VS-7375 trial shows promising preliminary results in KRAS G12D mutant solid tumors

Outlook

Verastem expects cash runway into the second half of 2026

Company plans to report interim safety and efficacy update on VS-7375 in 1H 2026

Verastem plans to engage with FDA for potential trials in PDAC and NSCLC in 1H 2026

Result Drivers

R&D - The increase of $4.2 million, or 16.9%, was primarily related to increased drug substance and drug product costs, increased contract research organization costs, and increased investigator trial costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$98.51 mln
Q3 Income from Operations
-$40.71 mln
Q3 Operating Expenses
$51.95 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Verastem Inc is $14.00, about 29.3% above its November 3 closing price of $9.90

Press Release: ID:nBw6l9C2Ka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)